Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 4,34€(+129,63%). Der Median liegt bei 4,34€(+129,63%).
Kaufen | 3 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Nicole Jones - IR Richard Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets Francois Brisebois - Oppenheimer and Company Justin Walsh - Jones Trading Brandon Folkes - Rodman & Renshaw John Vandermosten - Zacks SCR Boris Tolkachev - Freedom Broker Operator Greetings, and welcome to the Achieve Life Sciences Fourth Quarter and Year-End 2024 Earnings Call and Webcast. At this time all participants are in a listen-only mode.» Mehr auf seekingalpha.com
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Highlights Reached key milestones in the ORCA-OL long-term exposure trial, including completion of enrollment and meeting the requirement of 300 participants receiving six months of cumulative cytisinicline treatment, as required for the submission of the NDA Announced positive outcomes from two data safety monitoring committee (DSMC) reviews with no safety concerns in the ORCA-OL clinical trial Appointed Dr. Kristen Slaoui and Nancy Phelan to the Board of Directors, bringing extensive leadership experience in corporate strategy and commercialization Appointed Mark Oki as Chief Financial Officer to oversee the company's financial strategy and operational initiatives Announced the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for defining cytisinicline development as a treatment for vaping cessation “We are thrilled with our progress to date and excited to have the NDA submission on track for the end of next quarter, furthering our mission to bring cytisinicline to market as the first new FDA-approved nicotine dependence treatment in nearly 20 years,” said Rick Stewart, Achieve's Chief Executive Officer.» Mehr auf globenewswire.com
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will be presenting at the Barclays 27th Annual Global Healthcare Conference to be held March 11-13, 2025, in Miami, FL.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −11,88 Mio | 139,79% |
EBITDA | −11,63 Mio | 177,63% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 70,43 Mio€ |
Anzahl Aktien | 34,69 Mio |
52 Wochen-Hoch/Tief | 5,10€ - 1,86€ |
Dividenden | Nein |
Beta | 1,59 |
KGV (PE Ratio) | −1,79 |
KGWV (PEG Ratio) | 0,16 |
KBV (PB Ratio) | 3,41 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Achieve Life Sciences, Inc. ist ein pharmazeutisches Unternehmen im klinischen Stadium, das Cytisiniclin für die Raucherentwöhnung und Nikotinsucht in Kanada, den Vereinigten Staaten und Großbritannien entwickelt und vermarktet. Das Unternehmen bietet Cytisinicline an, ein pflanzliches Alkaloid, das mit Nikotinrezeptoren im Gehirn interagiert und so die Schwere der Nikotinentzugssymptome verringert. Es hat Lizenzvereinbarungen mit Sopharma AD und der Universität von Bristol. Das Unternehmen hat seinen Sitz in Vancouver, Kanada.
Name | Achieve Life Sciences |
CEO | Dr. Richard A. B. Stewart |
Sitz | Vancouver, bc USA |
Website | |
Industrie | Gesundheitswesen: Ausstattung und Produkte |
Börsengang | |
Mitarbeiter | 25 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ACHV |
Frankfurt | SP4P.F |
Düsseldorf | SP4P.DU |
München | SP4P.MU |
Assets entdecken
Shareholder von Achieve Life Sciences investieren auch in folgende Assets